The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs

BET bromodomain inhibitors are very promising novel anticancer agents, however, single therapy does not cause tumor regression in mice, suggesting the need for combination therapy. After screening a library of 2697 small molecule compounds, we found that two classes of compounds, the quinone-contain...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pei Y., Sokolowski, Nicholas, Guo, Su T., Siddiqi, Faraz, Atmadibrata, Bernard, Telfer, Thomas J., Sun, Yuting, Zhang, Lihong, Yu, Denise, Mccarroll, Joshua, Liu, Bing, Yang, Rui H., Guo, Xiang Y., Tee, Andrew E., Itoh, Ken, Wang, Jenny, Kavallaris, Maria, Haber, Michelle, Norris, Murray D., Cheung, Belamy B., Byrne, Jennifer A., Ziegler, David S., Marshall, Glenn M., Dinger, Marcel E., Codd, Rachel, Zhang, Xu D., Liu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346709/
https://www.ncbi.nlm.nih.gov/pubmed/27764794
http://dx.doi.org/10.18632/oncotarget.12640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346709/
https://www.ncbi.nlm.nih.gov/pubmed/27764794
http://dx.doi.org/10.18632/oncotarget.12640

Ejemplares similares